



INTRODUCING

ID NOW™ COVID-19

MOLECULAR. IN MINUTES™.
ON THE FRONT LINE.

Detects novel coronavirus in as little as 5 minutes^{1*}

- Leading molecular point-of-care (POC) platform in the United States, trusted by hospitals, physician offices and urgent care facilities nationwide
- High-quality molecular technology targeting COVID-19 RdRp gene
- Emergency Use Authorization (EUA) supports flexible near-patient testing environments
- Sample types tested direct or in viral transport media (VTM) include:
 - Throat swab
 - Nasal swab
 - Nasopharyngeal swab
- ID NOW™ platform designed with POC in mind



ID NOW™ COVID-19

SPEED – Positive result in as little as 5 minutes, negative results in 13 minutes.¹

Timely results enable healthcare professionals to make appropriate and more efficient treatment and infection control decisions.



ID NOW™ COVID-19

TECHNOLOGY – ID NOW™ utilizes proven isothermal molecular technology in an intuitive platform, providing the fastest molecular results in the market¹

EASE OF USE – Simplifying the test process

- Designed for near-patient testing in a variety of environments**
- Assay kit contains all necessary components for testing, including:
 - 24 tests
 - Swabs for sample collection
 - Pipettes
 - Positive and negative control swabs
- Room-temperature storage eliminates need for refrigeration

ORDER INFORMATION

PRODUCT NAME	PRODUCT CODE
ID NOW™ COVID-19 24 TEST KIT	190-000
ID NOW™ COVID-19 CONTROL KIT (12 POSITIVE, 12 NEGATIVE)	190-080

CPT Code: 87635

FOR MORE INFORMATION, CONTACT YOUR LOCAL ABBOTT REPRESENTATIVE OR VISIT ABBOTT.COM/POCT

The ID NOW™ COVID-19 EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of *in vitro* diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

*ID NOW™ COVID-19 detects positive results in as a little as 5 minutes. Negative results detected in 13 minutes.

**Please see ID NOW Instrument user manual for additional operating environment requirements.

1. Internal clinical data held on file.

© 2020 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only.

120006407-01 03/20

